Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Zhihong Zeng, Yue Xi Shi, Ismael J. Samudio, Rui Yu Wang, Xiaoyang Ling, Olga Frolova, Mark J Levis, Joshua B. Rubin, Robert R. Negrin, Elihu H. Estey, Sergej Konoplev, Michael Andreeff, Marina Konopleva

Research output: Contribution to journalArticle

Abstract

SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment interactions.We previously reported that bone marrow-derived stromal cells inhibit chemotherapy-induced apoptosis in acute myeloid leukemia (AML). Here we demonstrate that the CXCR4 inhibitor AMD3465 antagonized stromal-derived factor 1α (SDF-1α)-induced and stroma-induced chemotaxis and inhibited SDF-1α-induced activation of prosurvival signaling pathways in leukemic cells. Further, CXCR4 inhibition partially abrogated the protective effects of stromal cells on chemotherapy-induced apoptosis in AML cells. Fetal liver tyrosine kinase-3 (FLT3) gene mutations activate CXCR4 signaling, and coculture with stromal cells significantly diminished antileukemia effects of FLT3 inhibitors in cells with mutated FLT3. Notably, CXCR4 inhibition increased the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of the FLT3 inhibitor sorafenib. In vivo studies demonstrated that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals. These findings indicate that SDF-1α/CXCR4 interactions contribute to the resistance of leukemic cells to signal transduction inhibitor- and chemotherapy-induced apoptosis in systems mimicking the physiologic microenvironment. Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment.

Original languageEnglish (US)
Pages (from-to)6215-6224
Number of pages10
JournalBlood
Volume113
Issue number24
DOIs
StatePublished - 2009

Fingerprint

fms-Like Tyrosine Kinase 3
Chemotherapy
Acute Myeloid Leukemia
Liver
Protein-Tyrosine Kinases
Leukemia
Phosphotransferases
Drug Therapy
Bone
Myeloid Cells
Apoptosis
Stromal Cells
Bone Marrow
Signal transduction
Granulocyte Colony-Stimulating Factor
Chemotaxis
Coculture Techniques
Mesenchymal Stromal Cells
Signal Transduction
Animals

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R. Y., Ling, X., Frolova, O., ... Konopleva, M. (2009). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 113(24), 6215-6224. https://doi.org/10.1182/blood-2008-05-158311

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. / Zeng, Zhihong; Shi, Yue Xi; Samudio, Ismael J.; Wang, Rui Yu; Ling, Xiaoyang; Frolova, Olga; Levis, Mark J; Rubin, Joshua B.; Negrin, Robert R.; Estey, Elihu H.; Konoplev, Sergej; Andreeff, Michael; Konopleva, Marina.

In: Blood, Vol. 113, No. 24, 2009, p. 6215-6224.

Research output: Contribution to journalArticle

Zeng, Z, Shi, YX, Samudio, IJ, Wang, RY, Ling, X, Frolova, O, Levis, MJ, Rubin, JB, Negrin, RR, Estey, EH, Konoplev, S, Andreeff, M & Konopleva, M 2009, 'Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML', Blood, vol. 113, no. 24, pp. 6215-6224. https://doi.org/10.1182/blood-2008-05-158311
Zeng, Zhihong ; Shi, Yue Xi ; Samudio, Ismael J. ; Wang, Rui Yu ; Ling, Xiaoyang ; Frolova, Olga ; Levis, Mark J ; Rubin, Joshua B. ; Negrin, Robert R. ; Estey, Elihu H. ; Konoplev, Sergej ; Andreeff, Michael ; Konopleva, Marina. / Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. In: Blood. 2009 ; Vol. 113, No. 24. pp. 6215-6224.
@article{157c65e0aa8f4b0ca786f16300e93fc9,
title = "Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML",
abstract = "SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment interactions.We previously reported that bone marrow-derived stromal cells inhibit chemotherapy-induced apoptosis in acute myeloid leukemia (AML). Here we demonstrate that the CXCR4 inhibitor AMD3465 antagonized stromal-derived factor 1α (SDF-1α)-induced and stroma-induced chemotaxis and inhibited SDF-1α-induced activation of prosurvival signaling pathways in leukemic cells. Further, CXCR4 inhibition partially abrogated the protective effects of stromal cells on chemotherapy-induced apoptosis in AML cells. Fetal liver tyrosine kinase-3 (FLT3) gene mutations activate CXCR4 signaling, and coculture with stromal cells significantly diminished antileukemia effects of FLT3 inhibitors in cells with mutated FLT3. Notably, CXCR4 inhibition increased the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of the FLT3 inhibitor sorafenib. In vivo studies demonstrated that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals. These findings indicate that SDF-1α/CXCR4 interactions contribute to the resistance of leukemic cells to signal transduction inhibitor- and chemotherapy-induced apoptosis in systems mimicking the physiologic microenvironment. Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment.",
author = "Zhihong Zeng and Shi, {Yue Xi} and Samudio, {Ismael J.} and Wang, {Rui Yu} and Xiaoyang Ling and Olga Frolova and Levis, {Mark J} and Rubin, {Joshua B.} and Negrin, {Robert R.} and Estey, {Elihu H.} and Sergej Konoplev and Michael Andreeff and Marina Konopleva",
year = "2009",
doi = "10.1182/blood-2008-05-158311",
language = "English (US)",
volume = "113",
pages = "6215--6224",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

AU - Zeng, Zhihong

AU - Shi, Yue Xi

AU - Samudio, Ismael J.

AU - Wang, Rui Yu

AU - Ling, Xiaoyang

AU - Frolova, Olga

AU - Levis, Mark J

AU - Rubin, Joshua B.

AU - Negrin, Robert R.

AU - Estey, Elihu H.

AU - Konoplev, Sergej

AU - Andreeff, Michael

AU - Konopleva, Marina

PY - 2009

Y1 - 2009

N2 - SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment interactions.We previously reported that bone marrow-derived stromal cells inhibit chemotherapy-induced apoptosis in acute myeloid leukemia (AML). Here we demonstrate that the CXCR4 inhibitor AMD3465 antagonized stromal-derived factor 1α (SDF-1α)-induced and stroma-induced chemotaxis and inhibited SDF-1α-induced activation of prosurvival signaling pathways in leukemic cells. Further, CXCR4 inhibition partially abrogated the protective effects of stromal cells on chemotherapy-induced apoptosis in AML cells. Fetal liver tyrosine kinase-3 (FLT3) gene mutations activate CXCR4 signaling, and coculture with stromal cells significantly diminished antileukemia effects of FLT3 inhibitors in cells with mutated FLT3. Notably, CXCR4 inhibition increased the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of the FLT3 inhibitor sorafenib. In vivo studies demonstrated that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals. These findings indicate that SDF-1α/CXCR4 interactions contribute to the resistance of leukemic cells to signal transduction inhibitor- and chemotherapy-induced apoptosis in systems mimicking the physiologic microenvironment. Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment.

AB - SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment interactions.We previously reported that bone marrow-derived stromal cells inhibit chemotherapy-induced apoptosis in acute myeloid leukemia (AML). Here we demonstrate that the CXCR4 inhibitor AMD3465 antagonized stromal-derived factor 1α (SDF-1α)-induced and stroma-induced chemotaxis and inhibited SDF-1α-induced activation of prosurvival signaling pathways in leukemic cells. Further, CXCR4 inhibition partially abrogated the protective effects of stromal cells on chemotherapy-induced apoptosis in AML cells. Fetal liver tyrosine kinase-3 (FLT3) gene mutations activate CXCR4 signaling, and coculture with stromal cells significantly diminished antileukemia effects of FLT3 inhibitors in cells with mutated FLT3. Notably, CXCR4 inhibition increased the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of the FLT3 inhibitor sorafenib. In vivo studies demonstrated that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals. These findings indicate that SDF-1α/CXCR4 interactions contribute to the resistance of leukemic cells to signal transduction inhibitor- and chemotherapy-induced apoptosis in systems mimicking the physiologic microenvironment. Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=67650367598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650367598&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-05-158311

DO - 10.1182/blood-2008-05-158311

M3 - Article

VL - 113

SP - 6215

EP - 6224

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -